Advertisement
Advertisement

RNTX

R

Rein Therapeutics, Inc. Common Stock

1.43
USD
Sponsored
-0.09
-5.86%
Jan 29, 16:00 UTC -5
Closed
exchange

Pre-Market

1.41

-0.02
-1.40%

RNTX Earnings Reports

Positive Surprise Ratio

RNTX beat 14 of 32 last estimates.

44%

Next Report

Date of Next Report
Apr 06, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.21
Implied change from Q3 25 (Revenue/ EPS)
--
/
--
Implied change from Q4 24 (Revenue/ EPS)
--
/
-90.45%

Rein Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 14, 2025, RNTX reported earnings of -0.21 USD per share (EPS) for Q3 25, beating the estimate of -0.24 USD, resulting in a 14.22% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.41% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of -0.21 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Rein Therapeutics, Inc. Common Stock reported EPS of -$0.21, beating estimates by 14.22%, and revenue of $0.00, 0% as expectations.
The stock price moved down -7.41%, changed from $1.35 before the earnings release to $1.25 the day after.
The next earning report is scheduled for Apr 06, 2026.
Based on 4 analysts, Rein Therapeutics, Inc. Common Stock is expected to report EPS of -$0.21 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement